Pure Biologics (WAR:PUR) Total Liabilities : zł15.77 Mil (As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Pure Biologics Total Liabilities?

Pure Biologics's Total Liabilities for the quarter that ended in Sep. 2024 was zł15.77 Mil.

Pure Biologics's quarterly Total Liabilities declined from Mar. 2024 (zł22.73 Mil) to Jun. 2024 (zł17.49 Mil) and declined from Jun. 2024 (zł17.49 Mil) to Sep. 2024 (zł15.77 Mil).

Pure Biologics's annual Total Liabilities increased from Dec. 2021 (zł7.70 Mil) to Dec. 2022 (zł14.71 Mil) and increased from Dec. 2022 (zł14.71 Mil) to Dec. 2023 (zł20.85 Mil).

Pure Biologics Total Liabilities Historical Data

The historical data trend for Pure Biologics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pure Biologics Total Liabilities Chart

Pure Biologics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

15.97

21.83

7.70

14.71

20.85

Pure Biologics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Liabilities	Get a 7-Day Free Trial															52.16	20.85	22.73	17.49	15.77

Pure Biologics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Pure Biologics's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	7.993	+	(12.852	+	-1.7763568394003E-15
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	20.85

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	22.738	-	1.893
	=	20.85

Pure Biologics's Total Liabilities for the quarter that ended in Sep. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	15.736	+	(0.027	+	0.0019999999999999
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	15.77

Total Liabilities	=	Total Assets (Q: Sep. 2024 )	-	Total Equity (Q: Sep. 2024 )
	=	10.79	-	-4.975
	=	15.77

Pure Biologics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Pure Biologics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Pure Biologics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pure Biologics SA (WAR:PUR) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

ul. Dunska 11, Wroclaw, POL, 54-427

Website

http://www.purebiologics.pl

Pure Biologics SA is a Poland based biopharmaceutical company. It invests in the development of new, innovative (non-generic or biosimilar) biological drugs, medical and diagnostic products. It is mainly engaged in the research and development of the biologically active molecule in the drug development process. It specializes in the production and analysis of recombinant proteins and antibodies, contract studies of early product development phases, protein engineering, protein formulation, genomic sequencing, proteomics analysis and bioinformatics. Its projects include cancer immunotherapy, therapy of neurodegenerative diseases, diagnosis of tumors, and other partner projects.

Pure Biologics Headlines

No Headlines